Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

PT Kalbe Farma Tbk.

PTKFYPNK
Healthcare
Drug Manufacturers - General
$13.29
$-0.28(-2.03%)
U.S. Market opens in 8h 18m

PT Kalbe Farma Tbk. Fundamental Analysis

PT Kalbe Farma Tbk. (PTKFY) shows moderate financial fundamentals with a PE ratio of 14.48, profit margin of 10.16%, and ROE of 15.28%. The company generates $172.1B in annual revenue with moderate year-over-year growth of 7.16%.

Key Strengths

Cash Position138720.58%
PEG Ratio0.00
Current Ratio3.85

Areas of Concern

No major concerns flagged.
We analyze PTKFY's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 74.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B
74.8/100

We analyze PTKFY's fundamental strength across five key dimensions:

Efficiency Score

Excellent

PTKFY demonstrates superior asset utilization.

ROA > 10%
11.68%

Valuation Score

Excellent

PTKFY trades at attractive valuation levels.

PE < 25
14.48
PEG Ratio < 2
0.00

Growth Score

Excellent

PTKFY delivers strong and consistent growth momentum.

Revenue Growth > 5%
7.16%
EPS Growth > 10%
17.30%

Financial Health Score

Excellent

PTKFY maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
3.85

Profitability Score

Moderate

PTKFY maintains healthy but balanced margins.

ROE > 15%
15.28%
Net Margin ≥ 15%
10.16%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is PTKFY Expensive or Cheap?

P/E Ratio

PTKFY trades at 14.48 times earnings. This suggests potential undervaluation.

14.48

PEG Ratio

When adjusting for growth, PTKFY's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values PT Kalbe Farma Tbk. at 2.22 times its book value. This may indicate undervaluation.

2.22

EV/EBITDA

Enterprise value stands at 0.73 times EBITDA. This is generally considered low.

0.73

How Well Does PTKFY Make Money?

Net Profit Margin

For every $100 in sales, PT Kalbe Farma Tbk. keeps $10.16 as profit after all expenses.

10.16%

Operating Margin

Core operations generate 12.56 in profit for every $100 in revenue, before interest and taxes.

12.56%

ROE

Management delivers $15.28 in profit for every $100 of shareholder equity.

15.28%

ROA

PT Kalbe Farma Tbk. generates $11.68 in profit for every $100 in assets, demonstrating efficient asset deployment.

11.68%

Following the Money - Real Cash Generation

Operating Cash Flow

PT Kalbe Farma Tbk. produces operating cash flow of $17.36B, showing steady but balanced cash generation.

$17.36B

Free Cash Flow

PT Kalbe Farma Tbk. produces free cash flow of $13.36B, offering steady but limited capital for shareholder returns and expansion.

$13.36B

FCF Per Share

Each share generates $11797.12 in free cash annually.

$11797.12

FCF Yield

PTKFY converts 10.56% of its market value into free cash.

10.56%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

14.48

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.22

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.007

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.85

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.15

vs 25 benchmark

ROA

Return on assets percentage

0.12

vs 25 benchmark

ROCE

Return on capital employed

0.17

vs 25 benchmark

How PTKFY Stacks Against Its Sector Peers

MetricPTKFY ValueSector AveragePerformance
P/E Ratio14.4829.28 Better (Cheaper)
ROE15.28%820.00% Weak
Net Margin10.16%-19731.00% (disorted) Strong
Debt/Equity0.020.26 Strong (Low Leverage)
Current Ratio3.854.69 Strong Liquidity
ROA11.68%-17993.00% (disorted) Strong

PTKFY outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews PT Kalbe Farma Tbk.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

46.31%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

31.20%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

97.99%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ